Shanghai Runda Medical Technology Co., Ltd.

Shanghai Stock Exchange 603108.SS

Shanghai Runda Medical Technology Co., Ltd. EBITDA for the year ending December 31, 2023: USD 192.21 M

Shanghai Runda Medical Technology Co., Ltd. EBITDA is USD 192.21 M for the year ending December 31, 2023, a -12.84% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Shanghai Runda Medical Technology Co., Ltd. EBITDA for the year ending December 31, 2022 was USD 220.52 M, a 5.48% change year over year.
Shanghai Runda Medical Technology Co., Ltd. EBITDA for the year ending December 31, 2021 was USD 209.06 M, a 15.40% change year over year.
Shanghai Runda Medical Technology Co., Ltd. EBITDA for the year ending December 31, 2020 was USD 181.16 M, a 9.35% change year over year.
Shanghai Runda Medical Technology Co., Ltd. EBITDA for the year ending December 31, 2019 was USD 165.66 M, a 15.27% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

Shanghai Stock Exchange: 603108.SS

Shanghai Runda Medical Technology Co., Ltd.

CEO	Mr. Cheng Xu Zhang
IPO Date	May 27, 2015
Location	China
Headquarters	Xinghui (Landmark) Center
Employees	3,315
Sector	Health Care
Industries Medical Instruments Biotechnology Hospitals & Clinics Pharmaceuticals

Description

Shanghai Runda Medical Technology Co., Ltd. provides integrated medical laboratory services in China. It offers platform supply, laboratory design/renovation, laboratory standardization, and information management system services; medical solutions to help healthcare professionals in the areas of biochemistry, diabetes, POCT, immunoassay analyzer, and molecular biology diagnosis; professional technical services; and logistic services. The company was founded in 1999 and is based in Shanghai, China.

Key trends

Past 5 years